Holen Sie sich die Stockscreener-App
87.35
0.45%
0.39
Vorhandelsmarkt:
87.58
0.23
+0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Alcon Inc Aktie (ALC) Neueste Nachrichten
Is Alcon Inc. a good long term investmentRapidly growing investment returns - PrintWeekIndia
What analysts say about Alcon Inc. stockSignificant capital appreciation - jammulinksnews.com
What drives Alcon Inc. stock priceSuperior stock selection - jammulinksnews.com
Alcon Inc. Stock Analysis and ForecastRapid profit acceleration - Autocar Professional
September 19th Options Now Available For Alcon (ALC) - Nasdaq
Alcon Stock Gains Following UNITY VCS' Approval in Canada - MSN
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times Europe
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com Nigeria
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target By Investing.com - Investing.com South Africa
Alcon Adds Noninvasive Treatment Solution, Acquires LumiThera | Business | Jul 2025 - Photonics Spectra
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - VisionMonday.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon’s vitreoretinal-cataract system receives Health Canada approval By Investing.com - Investing.com South Africa
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon’s vitreoretinal-cataract system receives Health Canada approval - Investing.com
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Nasdaq
La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada - New Castle News
Alcon Eyes Vitreoretinal Surgery Market Expansion in LumiThera Deal - MarketScreener
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com Australia
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
Alcon's Bold Bet on Light Therapy: A New Dawn for Dry AMD and Retinal Dominance - AInvest
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
Alcon To Acquire LumiThera And Its Photobiomodulation Device - Nasdaq
Alcon to acquire LumiThera and its dry AMD light therapy device By Investing.com - Investing.com South Africa
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire
Do Options Traders Know Something About Alcon Stock We Don't? - MSN
Is it Apt to Retain Alcon Stock in Your Portfolio for Now? - MSN
LENSAR Stockholders Approve Merger with Alcon Research - TipRanks
Alcon Canada Earns Global Recognition as a Top Employer - Yahoo Finance
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Yahoo Finance
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
GLP-1 Drugs Show Promise in Reducing Risk of Age-Related Eye Diseases - Managed Healthcare Executive
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
0.58%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):